Ascendis Pharma

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (öffnet in neuem Tab)

  TradingView · 30.09.2026

• BioMarin and Ascendis Pharma Finalize Settlement and Licensing Agreement for Navepegritide (öffnet in neuem Tab)

  Kalkine Media · 30.09.2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (öffnet in neuem Tab)

  TradingView · 30.09.2026

• Ascendis Pharma Closes Warrant Exercise Window, Lifts Share Capital on September 29, 2026 (öffnet in neuem Tab)

  tipranks.com · 29.09.2026

• Form 4 Ascendis Pharma A/S For: 29 September By Investing.com (öffnet in neuem Tab)

  Investing.com Nigeria · 29.09.2026

• Ascendis Pharma Sinks After Novo Nordisk Exit Shock (öffnet in neuem Tab)

  tipranks.com · 29.09.2026

• ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC (öffnet in neuem Tab)

  MEXC · 29.09.2026

• Ascendis Pharma (ASND) Climbs to $230.05 as Shares Push Toward Upper Range - SuperTrend (öffnet in neuem Tab)

  siam.in · 28.09.2026

• Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $273 (öffnet in neuem Tab)

  Moomoo · 28.09.2026

• Ascendis Pharma Price Target Maintained With a $300.00/Share by Cantor Fitzgerald (öffnet in neuem Tab)

  Moomoo · 28.09.2026

• Ascendis Pharma (ASND) Could Be 28% Undervalued As It Reclaims TransCon Rights (öffnet in neuem Tab)

  Simply Wall Street · 26.09.2026

• Ascendis Pharma Falls as Investors Reassess Novo Rights Reversion and Pipeline Execution Risk (öffnet in neuem Tab)

  Quiver Quantitative · 23.09.2026

• Ascendis Pharma Sinks As Novo Deal Collapse Spooks Wall Street (öffnet in neuem Tab)

  tipranks.com · 23.09.2026

• Ascendis Pharma (ASND) Authorizes $400M Share Buyback (öffnet in neuem Tab)

  Yahoo Finance · 20.09.2026

• Ascendis Pharma (ASND) Stock Looks Near Fair Value On Infant Trial Data (öffnet in neuem Tab)

  Simply Wall Street · 18.09.2026

• Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost? (öffnet in neuem Tab)

  Yahoo Finance · 17.09.2026

• Ascendis Pharma: Back To Full Independence (NASDAQ:ASND) (öffnet in neuem Tab)

  Seeking Alpha · 16.09.2026

• H.C. Wainwright reiterates Ascendis Pharma stock rating on Novo deal end (öffnet in neuem Tab)

  Investing.com · 16.09.2026

• Ascendis regains obesity rights as Novo exits monthly GLP-1 deal (öffnet in neuem Tab)

  The Pharma Letter · 16.09.2026

• Ascendis Pharma (ASND) Reclaims Global TransCon Rights For Obesity And Heart Disease (öffnet in neuem Tab)

  Simply Wall Street · 16.09.2026

• Why Is Ascendis Pharma Stock Trading Lower on Tuesday? (öffnet in neuem Tab)

  TradingView · 15.09.2026

• Ascendis Pharma at Morgan Stanley conference: cash flow, growth and rights (öffnet in neuem Tab)

  Investing.com · 15.09.2026

• Ascendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite Buyback (öffnet in neuem Tab)

  Quiver Quantitative · 15.09.2026

• Raymond James Downgrades Ascendis Pharma to Outperform From Strong Buy (öffnet in neuem Tab)

  Yahoo Finance · 15.09.2026

• Raymond James downgrades Ascendis Pharma stock rating on partnership shift (öffnet in neuem Tab)

  Investing.com · 15.09.2026

• Novo walks away from $285M pact to develop monthly GLP-1 obesity drug with Ascendis (öffnet in neuem Tab)

  Fierce Biotech · 15.09.2026

• Ascendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share Buyback (öffnet in neuem Tab)

  Yahoo Finance · 15.09.2026

• Ascendis Pharma (NASDAQ: ASND) board okays discretionary $400M share buyback (öffnet in neuem Tab)

  Stock Titan · 15.09.2026

• Novo Nordisk deal ends as Ascendis (NASDAQ: ASND) takes back obesity drug rights, with more programs shifting over (öffnet in neuem Tab)

  Stock Titan · 15.09.2026

• Ascendis Pharma gains full rights to TransCon t... (öffnet in neuem Tab)

  Pluang · 15.09.2026